A Phase II Trial of RP-101 for the Treatment of Moderate to Severe Chronic Dry Eye Disease in Postmenopausal Women

Trial Profile

A Phase II Trial of RP-101 for the Treatment of Moderate to Severe Chronic Dry Eye Disease in Postmenopausal Women

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2018

At a glance

  • Drugs RP-101-Redwood Pharma (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Redwood Pharma
  • Most Recent Events

    • 09 Jul 2018 According to a Redwood Pharma media release, the company has submitted clinical trial application to a national authority and ethical committee to start this trial in Q3 assuming required approvals have been granted.
    • 26 Apr 2018 According to a Redwood Pharma media release, the capital injection provided by the company, now allows to initiate final preparations for this trial.
    • 01 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top